Nuclear Matrix Protein 22 Levels in Patients With Renal Transplantation

Kagebayashi, Yoriaki; Yoshida, Katsunori; Kitauchi, Takanori; Kimura, Shoki; Yoneda, Tatsuo; Takao, Masaya; Okajima, Eigoro; Hirao, Yoshihiko

doi:10.5980/jpnjurol1989.89.774

Search citation statements

Order By: Relevance

Paper Sections

Select...

Functional Role Of Blca-1 and Blca-4 In Bladder Carcinoge1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evaluation of NMP22 has been also used for the diagnosis of colorectal carcinoma [33] and as a rejection marker in kidney transplantation [34]. …”

Section: Functional Role Of Blca-1 and Blca-4 In Bladder Carcinogementioning

confidence: 99%

Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

Santoni

Catanzariti

Minardi

et al. 2012

Advances in Urology

View full text Add to dashboard Cite

Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients. Nevertheless, several factors, including cost and invasiveness, render cystoscopy not ideal for routine controls. Advances in the identification of specific alterations in the nuclear structure of bladder cancer cells have opened novel diagnostic landscapes. The members of nuclear matrix protein family BLCA-1 and BLCA-4, are currently under evaluation as bladder cancer urinary markers. They are involved in tumour cell proliferation, survival, and angiogenesis. In this paper, we illustrate the role of BLCA-1 and BLCA-4 in bladder carcinogenesis and their potential exploitation as biomarkers in this cancer.

show abstract

“…Evaluation of NMP22 has been also used for the diagnosis of colorectal carcinoma [33] and as a rejection marker in kidney transplantation [34]. …”

Section: Functional Role Of Blca-1 and Blca-4 In Bladder Carcinogementioning

confidence: 99%

Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

Santoni

Catanzariti

Minardi

et al. 2012

Advances in Urology

View full text Add to dashboard Cite

show abstract

Nuclear Matrix Protein 22 Levels in Patients With Renal Transplantation

Abstract: These results suggest that serum NMP22 is useful parameter of rejection in renal transplantation patients.

Cited by 1 publication

References 8 publications

Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

Contact Info

Product

Resources

About